BioCentury | Mar 14, 2017
Distillery Therapeutics

Infectious disease

...INDICATION: Tuberculosis (TB) Cell culture studies identified sansanmycin-based inhibitors of M. tuberculosis murX that could help...
...MIC 50 ) values of 37-180 nM. In in vitro enzymatic assays, the compounds inhibited murX...
...0.11-4.33 µM. Next steps could include testing the compound in animal models of TB. TARGET/MARKER/PATHWAY: Mycobacterium tuberculosis phospho-N-acetylmuramoyl-pentappeptidetransferase (murX)...
BioCentury | Oct 13, 2016
Distillery Therapeutics

Therapeutics: Mycobacterium tuberculosis decaprenyl-phosphate N-acetylglucosaminephosphotransferase (rfe; wecA); M. tuberculosis phospho-N-acetylmuramoyl-pentap

...In vitro and cell studies suggest muraymycin D1-based, dual inhibitors of Mycobacterium tuberculosis rfe and murX...
...the antibiotic muraymycin D1 and two of its amide analogs inhibited M. tuberculosis rfe and murX...
...animal models of TB. TARGET/MARKER/PATHWAY: Mycobacterium tuberculosis decaprenyl-phosphate N-acetylglucosaminephosphotransferase (rfe; wecA ); M. tuberculosis phospho-N-acetylmuramoyl-pentappeptidetransferase (murX...
Items per page:
1 - 2 of 2